EGFR-Positive NSCLC: What to Know

When you get diagnosed with non-small-cell lung cancer (NSCLC) that's positive for epidermal growth factor receptor (EGFR), information about the disease can feel overwhelming. But knowing more about EGFR-positive NSCLC can help give you peace of mind and tools you can use to advocate for the best care possible.

"My advice is to always advocate for yourself by staying informed, ask your doctor about new treatment options and clinical trials, and be clear about how your current treatment is affecting your life because it matters as much as the treatment itself," says Heather Suchan, a 41-year-old mom and nonsmoker with stage IV EGFR-positive non-small-cell lung cancer who lives in Los Angeles.

Lung cancer is the leading cause of cancer deaths around the world. But in the past few years, treatment has taken some huge leaps forward.

"I've been caring for lung cancer patients for a long time, and I've never seen the science move this fast," says Michael Zgoda, MD, an interventional pulmonologist and the medical director of outpatient operations at City of Hope Cancer Center Phoenix. "Patients I meet today have options that didn't exist when I started, and more are coming."

How Detection and Treatment Have Changed

At the turn of the century, doctors treated lung cancer as one disease with no separate types. In 2004, researchers discovered EGFR mutations, which sparked a wave of research and new treatment options over the next few decades.

"As our understanding of EGFR-mutated lung cancer biology deepens, new opportunities are emerging to develop more effective and durable treatments," says Michael Menefee, MD, a hematologist-oncologist with Cleveland Clinic.

"This is one of the most hopeful areas in all of lung cancer care right now. Just a few years ago, we had one main pill for this disease," Zgoda says. "Today, we have several strong options, and we keep finding better ways to use them."

Tyrosine kinase inhibitors (TKIs) block EGFR-positive NSCLC cells from growing and dividing. Experts have continued to improve these medications to help them work better, and doctors now have three "generations" of TKIs to work with:

	FDA-approved options	How they work
First-generation	erlotinib (Tarceva) gefitinib (Iressa)	Reversibly sticks to EGFR to slow down reproduction and destroy cancer cells
Second-generation	afatinib (Gilotrif) dacomitinib (Vizimpro)	Binds and stops EGFR from telling cancer cells to multiply
Third-generation	lazertinib (Lazcluze) mobocertinib (Exkivity) osimertinib (Tagrisso)	Binds to specific types of EGFR mutations to slow cancer growth more effectively

Third-generation TKIs are now the standard first treatment for EGFR-positive NSCLC. And a new type of TKI, called sunvozertinib (Zegfrovy) received quick approval after promising research findings.

Some drug combinations may offer even better results. "Two big advances stand out to me," Zgoda says. "First, we've learned that combining our best targeted pill, osimertinib, with chemotherapy can help many patients stay well longer."

"Second, a newer combination of two drugs, amivantamab and lazertinib, is helping patients live longer than we ever thought possible," Zgoda says. "That includes patients with less common EGFR mutations."

Amivantamab (Rybrevant) — a lab-created protein — targets lung cancer cells differently from TKIs. Together, amivantamab and lazertinib slow cancer progression better than one medication alone.

Doctors have also started using targeted drugs like these much earlier, Zgoda says. "Patients who have surgery for early-stage disease, or radiation for stage III disease, can now take a targeted pill afterward to lower the chance of the cancer coming back."

Even with these exciting new treatments, some people become resistant to them. Researchers are still working on more options to manage resistance and make treatment work even better.

The Latest Advances Studied in NSCLC Research and Clinical Trials

Current clinical trials for EGFR-positive NSCLC include different drug combinations, medication resistance solutions, and new methods of identifying your specific EGFR mutation.

"One area of particular excitement is the development of therapies targeting resistance mutations that emerge after osimertinib treatment," Menefee says.

For example, the EGFR C797S mutation happens in up to 26% of patients after treatment and currently lacks an approved targeted therapy, Menefee says. "Encouragingly, more than half a dozen investigational agents designed to target this mutation are currently being evaluated in clinical trials."

Fourth-generation TKIs may lower resistance

A new type of TKI in development blocks lung cancer cell growth by sticking to a different part of the cell. These fourth-generation TKIs can be even more specific when targeting cancer cells, which may help lessen resistance.

Studies in cells and animals have shown these drugs work well against lung cancer, but not many have made it to human trials yet.

Antibody-drug conjugates can home in on cancer cells

Antibody-drug conjugates pair monoclonal antibodies (artificial immune proteins) with a drug that destroys cancer cells. These treatments can focus on the cancer so nearby tissues have less damage.

"Think of them as 'smart missiles' that carry chemotherapy straight to the cancer cell," Zgoda says. Several are in trials right now for patients whose cancer has stopped responding to other treatments, he says.

New third-generation TKIs target mutations and cancer spread

Researchers are also developing new third-generation TKIs. Rezivertinib reaches the central nervous system, which may make it even more effective if the cancer has spread to your brain. Abivertinib targets T790M: a specific EGFR mutation.

Drug combinations may bypass resistance

Some cancer medications slow cancer growth, while others destroy cancer cells. Even if two medications have the same effect, they may work in different ways. Because of this, experts are studying different drug combinations to see which work best together.

Recent studied combinations include:

Targeted treatment combinations

capmatinib with nazartinib

osimertinib with sevotinib

osimertinib with trastuzumab-emtansine

tepotinib with gefitinib

tepotinib with osimertinib

Medications combined with chemotherapy

anlotinib

atezolizumab with bevacizumab (ABCP)

iparomlimab and tuvonralimab (QL1706)

ivonescimab

nivolumab

pembrolizumab

sintilimab

sintilimab with IBI305 (a version of bevacizumab)

toripalimab

Other combinations

afatinib with cetuximab

amivantamab with lazertinib

osimertinib with durvalumab

toripalimab with anlotinib

'Liquid biopsies' may offer more accurate tumor profiling

Some research focuses on how experts identify your NSCLC type. "On the horizon, I'm excited about simple blood tests that can track the cancer's DNA," Zgoda says.

These tests could soon tell your doctor whether a treatment is working, or whether the cancer is starting to change, before a scan ever shows it, Zgoda says.

A type of "liquid biopsy," this blood test measures circulating tumor (ctDNA): pieces of DNA released by tumor cells when they die. Researchers have studies planned to test how liquid biopsies can help them pick the right treatment and find out if it's working.

Finding Support in the Lung Cancer Community

Living with lung cancer can cause a wide range of emotions. Building a support system can help you feel less alone, get questions answered, and connect with people who understand what you're going through.

Over the years, a strong and highly engaged community has grown for people living with EGFR-positive lung cancer, Menefee says. "These organizations and support networks can play an invaluable role in helping patients navigate the emotional, practical, and medical challenges of their cancer journey."

"One of the best resources I found was my medical team and the connections they pointed me toward," Suchan says. "When I was first diagnosed, I connected with City of Hope, and that organization became my rock for treatment, biomarker testing, understanding my specific diagnosis, and finding community with others going through similar journeys."

Suchan and Zgoda also recommend organizations like:

"They have incredible resources specifically for EGFR NSCLC patients like support groups and educational materials that help you understand your mutation and treatment options," Suchan says. She also found a lot of empowerment in online communities and forums dedicated to EGFR-positive NSCLC patients.

But what made the biggest difference for Suchan was the support of the people around her. "I opened up to my friends and co-workers about my diagnosis and was so fortunate that many of them ended up having connections to cancer organizations and advocacy groups I never would have found on my own, including my City of Hope care team," she says.

"Sometimes the best resource is just being honest about what you're going through and letting people help you navigate it," she says. "Cancer can feel incredibly isolating, but I've learned that you don't have to go through it by yourself."

Taking Care of Your Mental Health With EGFR-Positive NSCLC

Lung cancer doesn't just affect your body; it can cause emotional distress and mental health challenges, too. Left unaddressed, these effects can even lead to anxiety and depression.

"Feeling anxious or low after a cancer diagnosis is very common," Zgoda says. "Many of my patients with EGFR-positive lung cancer never smoked, and some carry a strange guilt or shock about that, too. These feelings are real, and they are treatable."

Even with effective cancer treatment options and a better prognosis, you may still feel uncertain about the future and worry about financial pressures and relationship disruptions, Menefee says. Because of this, Menefee says it's common for his patients to report:

Anxiety and depression
Sleep problems
Trouble concentrating
Mood changes
Intimacy and sexual health concerns

Zgoda says he feels thankful when his patients tell him about mental health concerns. "That takes courage, and it matters just as much as anything on your scan," he says.

Getting support for anxiety and depression can help you handle treatment better and feel better day to day, Zgoda says. "So we treat it like any other symptom. We talk about it, we bring in counselors or medicines if needed, and we check on it at every visit."

Your job is not to stay positive — it's to be honest with your team so we can help, Zgoda says. "You are not weak, and you are not alone."

Your doctor may offer a referral to a mental health professional, who can provide treatments like cognitive behavioral therapy (CBT). CBT helps you change the way you think about your situation, which can improve anxiety.

They may also recommend practices that support mindfulness, including:

Yoga
Tai chi
Progressive relaxation

How to Advocate for Yourself With Your Care Team

By making decisions about your care together with your care team, you can raise the chances of your treatment working better and improve your quality of life.

"First, you have to be honest with your medical team about what you're experiencing," Suchan says. "Ask questions, push for answers, make sure your care team understands how you're feeling physically and emotionally, and be willing to explore other options."

You should feel empowered to speak up when symptoms, side effects, or quality-of-life concerns are not improving, Menefee says. "Effective cancer care is a partnership, and timely communication is essential to achieving the best possible outcomes."

Menefee also recommends bringing a trusted family member or caregiver to appointments, whenever possible. "An additional advocate can help communicate concerns, ask questions, and ensure important issues are addressed."

At the time of diagnosis, Zgoda recommends asking for full biomarker testing before treatment starts. "Finding an EGFR mutation changes everything about the plan, and it still gets missed sometimes," Zgoda says.

Ask about your treatment options

If your current treatment plan isn't working for you, you can ask your team about your options. Suchan was on intravenous (IV) infusions of a drug for over a year. "I was grateful as the drug was absolutely working by shrinking my tumors significantly, but the appointments were several hours, which was difficult to manage around our family's busy schedule," she says.

Suchan talked openly with her oncologist and care team about the time commitment and whether there were alternatives that would still be as effective. "Those conversations were so important as they kept me engaged in my treatment plan, and there was an open dialogue around what future options might be available," Suchan says.

It's also always OK to ask for a second opinion, especially at a center that sees a lot of EGFR-positive lung cancer, Zgoda says. "Good doctors welcome it."

Tell your team about side effects

Also let your team know if your side effects are getting unmanageable. "Be specific and be persistent," Zgoda says. "Instead of saying 'I don't feel great,' try: 'My rash has been getting worse for two weeks, it's keeping me up at night, and the cream isn't helping.'"

Zgoda recommends keeping a symptom log, recording each symptom, when it started, and how it affects your daily life. "That kind of detail moves teams to act," Zgoda says.

He also suggests these self-advocacy tips:

Use the patient portal or call the nurse line between visits. Don't save problems for your next appointment.
Ask direct questions: "What's our next step if this doesn't improve in two weeks?" or "Should we do a scan or a new biopsy to see what's going on?"
If your cancer seems to be growing, ask whether you need new testing, such as a tissue or blood biopsy, to find out why. The reason for the growth often points to the next treatment.

"A treatment isn't truly working if it's making your life miserable," Zgoda says. And you usually don't have to choose between the two, he says.

Most side effects from these pills, like rashes, diarrhea, mouth sores, and nail problems, can be managed with early, simple steps, like a small dosage change, Zgoda says. "But we can only fix what we know about, so I need patients to tell me early, not tough it out."

Act fast for urgent symptoms

Zgoda tells his patients to call the team right away if they notice these symptoms:

New or worse shortness of breath, or breathing that feels harder than usual
Coughing up blood
A bad headache that won't quit
New confusion
Sudden changes in vision, balance, or speech
Chest pain
A fever, especially if you're on treatment
New pain in your bones or back that keeps getting worse
Swelling or pain in one leg, which can be a sign of a blood clot
Not being able to eat, drink, or keep fluids down

If something is new, getting worse, or worrying you, call, Zgoda says. "You will never bother us. I would much rather hear about 10 small things than miss one big one."

Consider palliative care

The goal of treatment for EGFR-positive NSCLC isn't just more time — it's more good time, Zgoda says. To help his patients get more good time, Zgoda brings in the palliative care team early on.

When you hear "palliative," you may think "end of life," but that's not what it means, he says. "It's a team of experts in comfort and quality of life who work alongside your cancer care, at any stage. Studies show patients who get this kind of support feel better and often live longer."

Living With EGFR-Positive NSCLC? Here’s What You Should Know